MLTX — MoonLake Immunotherapeutics Share News
0.000.00%
Last trade - 00:00Brief: Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed
MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings Summary
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial (updated)
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
Switzerland's MoonLake Q2 net loss narrows as expenses fall
Brief: MoonLake Immunotherapeutics Q2 EPS USD -0.84
Swiss stocks - Factors to watch on August 3
U.S. STOCKS ON THE MOVE-Broadcom, Micron, Qualcomm
U.S. STOCKS ON THE MOVE-Broadcom, Chemours, Qualcomm
MoonLake Immunotherapeutics slides after $200 mln share sale
Brief: Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share
MoonLake Immunotherapeutics falls on planned $150 mln equity raise
Brief: Moonlake Immunotherapeutics Says U.S. FDA Accepts MIRA And VELA-TEEN Trial Data For Sonelkimab BLA Submission
U.S. STOCKS ON THE MOVE-AbbVie, CrowdStrike, PayPal
U.S. STOCKS ON THE MOVE-Enhabit, Ethos Technologies, gold miners
U.S. STOCKS ON THE MOVE-Merck, Alphabet, JPMorgan Chase
U.S. STOCKS ON THE MOVE-Eli Lilly, Domino's, Novo Nordisk
MoonLake rises as spine‑inflammation drug shows benefit, secures new funding
U.S. STOCKS ON THE MOVE-DoorDash, Duolingo, Gap